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Abstract 
This commentary highlights the findings by Kessinger et al. (Theranostics 2011; 1: 263-275) 
that dynamic T2*-weighted magnetic resonance imaging (MRI) of cyclic RGD peptide-encoded 
superparamagnetic polymeric micelle (SPPM) nanoparticles allows quantitative analysis of 
tumor integrin αvβ3 expression, which can exclude the effect of blood volume and extra-
vascular signal components and thus provide less biased tumor contrast and receptor speci-
ficity of probes. 
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Targeted  nanoprobes  have  made  the  field  of 
molecular imaging an exciting arena with capabilities 
of delivering contrast agents to the desired site in vivo 
[1-3].  Targeted nanoprobes have been employed in a 
variety of imaging modalities such as positron emis-
sion  tomography  (PET),  single  photon  emission 
computed  tomography  (SPECT),  computed  tomog-
raphy (CT), magnetic resonance imaging (MRI) and 
optical imaging [4-6]. Among the imaging modalities, 
MRI is a powerful medical diagnostic imaging tech-
nique  for  soft  tissue  imaging  [7].  Magnetic  nano-
probes have been around for a while in the field of 
MRI  due  to  their  exceptional  spatial  and  temporal 
contrast  enhancement  [7-8].  Iron  oxide  nanoparticle 
(IONP) is one of the most adopted nanoprobes for T2 
weighted MRI studies. Several IONP formulas have 
been approved for clinical application, for example, 
Ferumoxide (Endorem®-Europe, Feridex® in the USA 
and Japan) and Ferucarbotran (Resovist®-Europe and 
Japan)  [9-13].  Ultra-small  superparamagnetic  iron 
oxide (USPIO) nanoparticles have shown potential in 
the imaging of molecular biomarkers such as integrins 
[12,  14-15].  Integrins  are  heterodimeric  transmem-
brane glycoproteins, a family of adhesion molecules 
which have been shown to play a major role in angi-
ogenesis and tumor metastasis [16]. The αvβ3 integrin 
is significantly over-expressed on activated endothe-
lial cells during angiogenesis but not on dormant en-
dothelial cells. A salient feature of αvβ3 integrin is that 
it binds to extracellular matrix proteins via the three 
amino  acid  sequence  arginine–glycine–aspartic  acid 
(RGD). It is indicated that inhibition of integrin αvβ3 
activity  by  cyclic  RGD  peptides,  monoclonal  anti-
bodies and peptidomimetics may trigger endothelial 
cell apoptosis and result in inhibition of angiogenesis 
[17-18].  
Data related to early events of binding and cel-
lular  uptake  of  targeted  nanoprobes  in  cancer  cells 
will  reveal important insights  on the critical factors 




oping  new  anti-angiogenic  agents  and  for  response 
evaluation, early time point kinetic studies are very 
important,  where  targeted  nanoprobes  can  specifi-
cally bind to the cell surface receptors on the tumor 
endothelium  from  circulating  blood.  Gadolinium 
based T1 based MRI contrast probes have been used 
for  studying  kinetic  parameters  using  DCE-MRI 
[19-20].  Low  molecular  weight  probes  such  as 
Gd-DTPA  worked  well  in  tumor  perfusion  studies 
and  pharmacokinetic  parameters  were  measured 
[21-22]. However, these probes are non-specific and 
require millimolar concentrations for detection, indi-
cating  lack  of  sensitivity.  Developing  sensitive  and 
target specific nanoprobes for DCE-MRI would pro-
vide more reliable kinetic data.   
In this volume of Theranostics Kessinger et al. [23] 
examined  for  the  first  time  early  time  point  kinetic 
studies of the binding events of targeted nanoprobes 
in  vivo  using  time-resolved  MRI.  In  this  work,  ul-
tra-sensitive  superparamagnetic  polymeric  micelle 
(SPPM)  nanoprobes  were  employed  to  quantify  the 
targeting kinetics of c(RGDfK) (cRGD)-encoded SPPM 
to  angiogenic  endothelium  in  subcutaneous  lung, 
breast  and  glioblastoma  xenograft  models  in  mice 
using T2*-weighted HTR-MRI. A cluster of SPIO na-
noparticles loaded into the core-shell of the polymeric 
micelle was used in the three different animal models. 
The  nanoprobes  were  shown  to  increase  the  trans-
verse relaxivity of the nanoprobes to over 400 Fe mM-1 
s-1  at  7T,  a  4-fold  higher  relaxivity  compared  to 
Feridex. T2*-weighted HTR-MRI with 1.3 s temporal 
resolution over 30 min shed light on the early phase of 
the  targeting  kinetics  of  αvβ3-specific  SPIO  nano-
probes  in  different  tumor  xenografts  models.  SPIO 
nanoprobes  conjugated  with  αvβ3-specific  cyclic 
RGDfK  (cRGD)  peptide  and  non-targeting  cyclic 
RADfK (cRAD) as a control, were evaluated for dif-
ference in MR signal intensity (SI) over time. Com-
parison of the targeted and non-targeted SPPM data 
allowed for the subtraction of signal intensity contri-
butions from blood concentration, clearance and en-
hanced permeability and retention (EPR) effect. Ac-
cumulation  rates  (Ka)  in  the  initial  phase  (<5  min) 
were found to be similar across all the three tumor 
models.  However,  a  sustained  accumulation  of  tar-
geted cRGD-SPPM over 30 min was observed.  
DCE-MRI is usually applied for characterization 
of abnormalities of perfusion, endothelial and epithe-
lial permeability with T1 weighted contrast imaging 
[24]. In this study, a new opportunity for characteriz-
ing the tumor specific targeting kinetics of nanoparti-
cles by T2 weighted contrast imaging is reported and 
the  initial  results  of  αvβ3  integrin  receptor  density 
quantification are achieved. Since the signal intensity 
curves of each region of interest (ROI) can be derived 
from T2 images, kinetic modeling analysis is able to 
estimate  the  pharmacokinetics  of  cRGD-SPPM  con-
trast  agent  which  reflects  the  tumor  integrin  level. 
Considering the non-specific binding of cRGD-SPPM 
via the leakage of contrast agent from capillary to the 
extravascular  parenchymal  space,  they  also  studied 
the cRAD-SPPM as a non-targeting control. By sub-
tracting the mean value of cRAD from cRGD curves, a 
compartment  which  only  represents  the  specific 
cRGD  concentration  is  achieved  and  relates  to  the 
specific accumulation rate independently.  
As  is  the  case  with  the  two-  or 
three-compartment kinetic modeling widely used in 
PET  dynamic  studies,  one-compartment  modeling 
from which non-targeting contrast agent is subtracted 
is also a direct method for receptor density study. The 
one-compartment model is easier to fit and more effi-
cient for quantification of parameters; however, it is 
premised on accurate subtraction. For PET quantita-
tive analysis of receptor density, the optimized model 
is  comparable  to  the  three  compartment  model  for 
binding potential measurement.   
In  conclusion,  this  paper  describes  early  time 
point kinetic binding studies of targeted nanoprobes 
that  offer  new  opportunities  in  quantitative  charac-
terization of the targeting kinetics of cancer-specific 
nanoparticles to their intended biological targets in an 
intact  animal.  The  data  provide  less  biased  tumor 
contrast  and  receptor  specificity  of  probes  and  can 
exclude the effect of blood volume and extra-vascular 
signal components.  
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